New Auto-Injector lets MG patients Self-Dose at home

NCT ID NCT06471361

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether people with generalized myasthenia gravis (gMG) can safely and effectively use an auto-injector to give themselves the drug zilucoplan at home. Thirty-one adults who were already on a stable dose of zilucoplan took part. The main goal was to see if they could deliver the full dose correctly each time, with safety and tolerability also monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zilucoplan
What this could lead to: If successful, this could make it easier for people with generalized myasthenia gravis to self-administer their medication at home, improving convenience and independence.
What could go wrong: This is a small, completed Phase 3 study focused on device usability, not on proving the drug works. The results may not apply to all patients, and self-injection errors could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Dv0013 40605

Poznan, Poland
Dv0013 40609

Katowice, Poland
Dv0013 40759

Krakow, Poland
Dv0013 40760

Oxford, United Kingdom
Dv0013 50555

Austin, Texas, 78759, United States
Dv0013 50556

Chapel Hill, North Carolina, 27599, United States
Dv0013 50628

New Haven, Connecticut, 06511, United States
Dv0013 50634

Tampa, Florida, 33612, United States
Dv0013 50635

Columbus, Ohio, 43221, United States
Dv0013 50636

Greenfield, Wisconsin, 53228, United States
Dv0013 50648

Columbia, Missouri, 64212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.